Piper Sandler Raises Corcept Therapeutics (NASDAQ:CORT) Price Target to $78.00
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) had its price target increased by analysts at Piper Sandler from $67.00 to $78.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Piper Sandler’s price objective indicates a potential upside of 28.76% from the stock’s previous close. […]
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) had its price target increased by analysts at Piper Sandler from $67.00 to $78.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Piper Sandler’s price objective indicates a potential upside of 28.76% from the stock’s previous close. […]
